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BACKGROUND: Validated objective biomarkers are needed for patients with renal cell carcinoma (RCC) to guide patient management
and define high-risk populations for follow-up or for therapeutic purposes.
METHODS: Patients undergoing nephrectomy for RCC (n¼286 all stages, 84% with conventional clear cell type) were included with a
median duration follow-up of 5 years. The prognostic significance of pre-operative haematological and biochemical variables, including
C-reactive protein (CRP) values were examined and whether they added additional information to a recently published pre-
operative scoring system was determined.
RESULTS: C-reactive protein was the most significant predictor of overall survival (OS; w
2¼50.9, Po0.001). Five-year OS for patients
with CRPp15mgl
 1 vs 415mgl
 1 was 72% (95% CI 65–78%) and 33% (95% CI 23–44%), respectively. Similar results were seen
for cancer-specific survival (CSS) and disease-free survival. On multivariate analysis, CRP remained highly significant for CSS
(w
2¼17.3, Po0.0001) and OS (w
2¼9.8, Po0.002), in addition to other pre-operative variables including log of neutrophil/
lymphocyte ratio, red blood cell count and white cell count. C-reactive protein was significant in addition to the pre-operative
nomogram score (w
2¼12.5, P¼0.0004 for OS, w
2¼16.2, P¼0.0001 for CSS and w
2¼8.6, P¼0.003 for DFS) and was still
significant when other pre-operative variables were included.
CONCLUSION: C-reactive protein and other haematological and biochemical variables have independent prognostic significance in RCC
and may enhance pre-operative scoring systems.
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Renal cancer accounts for approximately 3% of adult malignancies
with approximately 210000 cases per year worldwide (GLOBOCAN
2002) (http://www-dep.iarc.fr). Approximately, 70% of patients
have clinically localised disease at presentation, but 20–30% of
these develop metastatic disease after surgery (Bukowski, 2009).
Patients are usually followed up with intermittent imaging tests
with a multiplicity of regimens proposed (Rouviere et al, 2006).
In the curative setting, therefore, there is a need for prognostic
markers that can help to stratify patients according to risk, to
enable follow-up schedules to be individualised and to tailor
eligibility criteria for trials of neo-adjuvant and adjuvant therapies.
In the metastatic setting, such factors may help with patient
selection for newer targeted therapies to minimise toxicity and
maximise resources.
Many prognostic algorithms or models combine elements of the
TNM staging system with tumour grade and combinations of
pathological or clinical factors (Galfano et al, 2008; Lane and
Kattan, 2008). However, estimates of risk may be relatively wide
for individual patients, not applicable to all subtypes or stages of
RCC and some models have not been independently validated.
Additionally parameters such as pathological stage and grade are
subject to intra- and inter-observer variabilities. More recently,
algorithms based on pre-operative variables have been developed.
One of these is widely applicable and incorporates age, gender,
symptom score, CT-derived size and T stage and presence or
absence of metastatic disease (Karakiewicz et al, 2009). Such
models have potential value in determining treatment modality,
surgical strategy and neo-adjuvant targeting and patient manage-
ment pre-operatively.
The area of defining new prognostic markers is of active interest
(George and Bukowski, 2007; Crispen et al, 2008). Biomarkers in
fluids offer the opportunity for more objective and reproducible
measurement before operation. Recent examples include the
prognostic significance of pre-operative serum sodium and
urinary cathepsin D levels (Vasudev et al, 2008, 2009) and CRP
(Ito et al, 2006; Karakiewicz et al, 2007; Komai et al, 2007; Kawata
et al, 2008; Lamb et al, 2008; Ramsey et al, 2008; Iimura et al,
2009). In this study we have comprehensively analysed the
potential pre-operative prognostic significance of a panel of
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shaematological and biochemical variables, including CRP in
patients with all stages and histological subtypes of RCC under-
going nephrectomy, and examined their potential utility in
combination with a recently published pre-operative (Karakiewicz
et al, 2009) scoring system.
PATIENTS AND METHODS
Patients
Patients undergoing potentially curative or cytoreductive nephrec-
tomy in Leeds between 1999 and 2006 and who consented to
take part were included, excluding patients with familial VHL or
polycystic kidney disease. All histological subtypes were included
in the analysis (although some separate analyses were also
undertaken on patients with clear cell histology only), reflecting
the aims of the study in investigating the pre-operative utility of
CRP that is, at a time when the histological subtype would be
unknown. The study was approved by the Leeds Research Ethics
Committee. Clinico-pathological data was largely obtained pro-
spectively with nodal or metastatic disease status determined
by CT scan, and all haematological and biochemical variables
were measured routinely on pre-operative venous blood samples.
C-reactive protein level was measured by a polyethylene glycol
(PEG)-enhanced immunoturbidimetric assay on the Siemens
Advia 1650 (Siemens Healthcare, Erlangen, Germany).
The pre-operative nomogram score using the variables of
gender, age, tumour size and T stage from imaging and a symptom
classification score (Karakiewicz et al, 2009) were calculated for
each patient. Patients with T4 disease on CT staging were treated as
T3, as the published nomogram did not include T4.
Statistical methods
The design and analysis of this retrospective study was conducted
according to ReMARK guidelines (McShane et al, 2005). Survival
curves were constructed using the life table method, with
significance being determined using the log-rank test. Multivariate
analysis of survival data used the proportional hazards model with
a forward stepwise approach using a P-value for inclusion of 0.01
because of the inclusion of so many variables. Harrell’s c-index
(Harrell et al, 1982) was used to quantify the predictive accuracy of
both univariate survival models and multivariate Cox models. This
gives a value between 50%, for predictive capacity of the model
being no better than random, and 100% for full predictive capacity.
The 12 patients with unknown grades were recoded as grade 3, as
their survival most closely matched that grade. A similar method
was used for the few patients who had unknown values for stage or
T stage and for the biochemical/blood variables. This enabled all
the patients to be included in the Cox model runs. Additional
model runs performed, excluding these patients, demonstrated
that this approach was not creating bias. Variables were treated as
continuous, or with simple, for example, log transformations in the
Cox models, unless analysis using optimum cut-points of the
variable gave substantially larger w
2 values in the Cox model. For
CRP, a log transformation was most appropriate. The CRP values
reported as o5 were all assumed to be 2.5 for the purposes of the
Cox model analyses. An optimum cut-point was one that
maximised the w
2 (or b coefficient in the Cox model) from the
log-rank test, comparing survival above and below that cut-point.
The Cox models were run with and without the pre-operative
model scores to determine whether the accuracy of prediction of
survival was improved when CRP and other factors were added to
it. Correlations of other factors with the log of CRP values were
examined using stepwise linear regression with all variables
considered as continuous (detailed results not shown). The r
2
values in the multivariate linear regression indicate how much of
the variability in CRP values is explained by the factors included.
All P-values are two-tailed. Our 1, 2 and 5-year survival figures
were compared with those previously published using the pre-
operative nomogram (Karakiewicz et al, 2009) interpolating
between the survival percentages given for different scores in
their paper and averaging these over our whole patient population.
Survival was determined based on operation date. DFS was
defined from that date until relapse with patients presenting
without metastases or with metastases, which were resected being
considered as disease free. Patients dying of other causes without
relapsing were considered censored for DFS at their date of death.
RESULTS
The demographics and clinico-pathological characteristics of the
286 patients with CRP values available are shown in Table 1.
Median follow-up was 5 years. Analyses, which included treatment
and its effects, did not alter the findings and so are not reported.
Univariate analysis of CRP and survival
C-reactive protein was a highly significant predictor of OS, cancer-
specific survival (CSS) and DFS in all RCC histological subtypes
examined (Figures 1A–C). Although a log transformation of CRP
was used in the Cox model a cut-point of 15mgl
 1 was used when
depicting survival and DFS differences, as this incorporated much
of the effect. The (univariate) predictive capacity of log of CRP,
using Harrell’s c-index was 70% for OS, 77% for CSS and 73% for
DFS. There was no predictive effect of CRP on non-cancer survival
(Figure 1D). The survival effect was similar in clear cell and non-
clear cell subtypes (Figure 2).
Multivariate (Cox model) analysis
Univariate and multivariate Cox model results for CSS, OS and
DFS are shown in Table 2. C-reactive protein is still highly
significantly predictive of survival after inclusion of all the other
significant factors for CSS, OS and DFS. Other factors that were
independent predictors of CSS on multivariate analysis included
tumour stage, grade, WBC, RBC and log of neutrophil/lymphocyte
ratio. Log of CRP was the most predictive factor for OS (c-index of
70%) and the second most predictive factor after stage for CSS,
increasing the predictive capacity from 81 to 86%. On multivariate
analysis of factors for OS, the additional independent predictors
included the presence of metastases, necrosis, MVI, RBC and WBC.
For DFS, the only independent predictors are CRP, age, stage and
MVI. C-reactive protein was the second most predictive factor
after stage for DFS, increasing the predictive capacity from 77 to
84%.
Landmark analyses pre- and post-1 year
Cox multivariate analysis of CSS, restricted to deaths within
the first year, showed the log of neutrophil/lymphocyte ratio
(w
2¼14.5, P¼0.0001) and WBC (w
2¼6.1, P¼0.01) to be signi-
ficant, plus log of CRP (w
2¼23.4, Po0.0001), the presence of
metastases (w
2¼12.0, P¼0.0005), N stage ( ve vs þve, w
2¼10.6,
P¼0.001) and maximum tumour size (p50 vs 51–100 vs 4100,
w
2¼9.3, P¼0.002). Analysis restricted to patients who had
survived more than 1 year showed stage (w
2¼25.2, Po0.0001),
grade (w
2¼9.4, P¼0.002), necrosis (w
2¼6.4, P¼0.01) and sodium
(w
2¼8.5, P¼0.004) to be the only relevant factors. C-reactive
protein was still highly significant univariately in this latter
analysis (w
2¼19.1, Po0.0001), but was no longer significant
multivariately because of its correlations with stage, grade and
necrosis. C-reactive protein was significantly correlated with many
of the variables analysed (data not shown).
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Pre-operative nomogram score gave excellent separation of the
CSS, OS and DFS curves with similar survival estimates to the
original published nomogram estimates (Karakiewicz et al, 2009)
(Figure 3A). The predictive accuracy of this nomogram on our
data, using Harrell’s c-index, was 74% (compared with 86% for
the data on which it was validated (Karakiewicz et al, 2007)). The
slight early survival advantage in our series appeared to derive
predominantly from the patients with higher nomogram scores,
and therefore poorer prognosis.
In Cox model analysis, CRP is significant in addition to the
nomogram score (w
2¼12.5, P¼0.0004 for OS, w
2¼16.2,
P¼0.0001 for CSS and w
2¼8.6, P¼0.003 for DFS), although the
increase in predictive accuracy, as measured by Harrell’s c-index,
was uniformly only about 2%. However, to take OS as an example,
predicted survival curves from the Cox model for CRP below and
above 15, are still widely separated (Figure 3B), corresponding to
the 2% improvement in predictive accuracy after allowing for
nomogram score, with an individual having CRPp15 having an
86% 5-year survival compared with 69% for a patient with
CRP415 even after allowing for the nomogram score. Including
the other significant pre-operative variables from Table 2, CRP was
still significant for OS (w
2¼7.8, P¼0.005), CSS (w
2¼13.6,
P¼0.0002) and DFS (w
2¼11.2, P¼0.0008). The nomogram score
was not as predictive as the other pre-operative factors from
Table 2 (CRP, metastases, RBC and WBC) for OS and does not
provide extra prognostic information for survival in addition to
these variables.
Table 1 Characteristics of the 286 renal cancer patients included in the
study
Characteristics n (%) Characteristics
Median (range)
n (%) for subsets
Age (yrs)
Median 63 Hb (g per 100ml)
a 13.6 (7–20)
Range 29–86
Gender
Male 168 (59) RBC ( 10
12 cells per l) 4.6 (2.8–8.0)
Female 118 (41) p4.25 70 (24)
44.25 215 (75)
Unknown 1 (0.3)
Histological subtype
Clear cell 240 (84) WBC ( 10
9 cells per l) 7.7 (3.2–17.6)
Papillary 25 (9) p9.5 229 (80)
Chromophobe 12 (4) 49.5 56 (20)
Unknown 1 (0.3)
Collecting duct 3 (1)
Unclassified 6 (2)
Grade
1 7 (2) Neutrophils
( 10
9 cells per l)
5.2 (2.25–14.79)
2 I79 (28) p4.9 124 (43)
3 117 (41) 44.9 160 (56)
4 72 (25) Unknown 2 (1)
Unknown 12 (4)
Max tumour size (cm)
Median 6.1 Lymphocytes
( 10
9 cells per l)
1.7 (0.26–7.35)
Range 0–18 p1 37 (13)
41 248 (87)
Unknown 1 (0.3)
Necrosis
Present 94 (33) Monocytes
( 10
9 cells per l)
a
0.41 (0.09–1.11)
Absent 183 (64) Unknown 1 (0.3)
Unknown 9 (3)
MVI
Present 118 (41) Neuts/Lymphs
b 2.9 (0.75–30.6)
Absent 164 (57) Unknown 3(1)
Mean 3.8
Unknown 4 (1) Mean log 3.2
pT stage
1 117 (41) Platelets
( 10
9 cells per l)
283 (78–884)
2 35 (12) 0–360 215 (75)
3 131 (46) 361–884 68 (24)
4 2 (1) Unknown 3 (1)
Unknown 1 (0.3)
N stage
0 251 (88) Sodium (mmoll
 1) 140 (127–147)
1+ 35 (12) 127–138 95 (33)
139–147 190 (66)
Unknown 1 (0.3)
Mean 139.5
M stage
0 228 (80) Potassium (mmoll
 1) 4.4 (3.1–6.0)
1 58 (20) p4.3 126 (44)
44.3 154 (54)
Unknown 6 (2)
TNM stage
I 109 (38) Creatinine
(mmoll
 1)
b
95 (52–1106)
Table 1 (Continued)
Characteristics n (%) Characteristics
Median (range)
n (%) for subsets
II 28 (10)
III 90 (31)
IV 58 (20)
Unknown 1 (0.3)
Urea (mmoll
 1)
a 5.7 (2–28.8)
CT T stage
1a 75 (26) CRP (mgl
 1) 6.4 (o5–266)
1b 75 (26) p15 207 (72)
2 65 (23) 415 79 (28)
3 43 (15)
4 11 (4)
Unknown 12 (6)
CT tumour size (cm)
Median 6.0
Range 2–21
Unknown 22 (8)
Symptom score
1 130 (45)
2 99 (35)
3 56 (20)
Unknown 1 (0.3)
Abbreviations: CRP¼C-reactive protein; CT¼computed tomography; Hb¼haemo-
globin; K¼potassium; Lymphs¼lymphocytes; M¼metastasis; monos¼monocytes;
MVI, microvascular invasion; N¼nodal; Na¼sodium; Neuts¼neutrophils;
RBC¼red blood cells; T¼tumour; WBC¼white blood cell count. Reference
ranges are: Hb level, female: 11.5–16.0 g per 100ml, male: 13.5–18.0 g per 100ml;
WBC, 4.0–11.0 10
9 cells per l; RBC, 3.8–5.8 10
12 cells per l; neutrophil count,
2.00–7.5 10
9 cells per l; monocyte count, 0.2–0.8 10
9 cells per l, platelets count,
150–400 10
9 cells per l; sodium level, 135–145mmoll
 1; potassium level,
3.5–5.0mmoll
 1; creatinine level, female: 70–100mmoll
 1,male:80–115mmoll
 1;u r e a
level, 2.1–8.0mmoll
 1;C R P o10mgl
 1.
aIndicates coded as a continuous variable, no
obvious cut-points.
bIndicates coded as a log transformation, again no obvious cut-points.
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Po0.001), and this changed only imperceptibly when CRP was
analysed as a categorical variable above and below 15 (r¼0.53,
Po0.001). C-reactive protein appeared to provide most additional
explanatory power in the lower nomogram score ranges, although
the numbers became small. For CSS, there was an effect in the
o100 range, with 3 out of 104 deaths in the low CRP group and 2
out of 10 in the high CRP group (w
2¼10.7, P¼0.001). For DFS,
CRP again gave additional prognostic information in the good
nomogram score categories (o100: low CRP vs high CRP w
2¼7.3,
P¼0.007 and 100–150: w
2¼5.7, P¼0.02).
DISCUSSION
Previous studies have reported the independent prognostic
significance of CRP measured before nephrectomy in patients
with RCC in studies ranging from 40 to 313 patients (Jabs et al,
2005; Ito et al, 2006; Karakiewicz et al, 2007; Komai et al, 2007;
Kawata et al, 2008; Lamb et al, 2008; Ramsey et al, 2008; Iimura
et al, 2009). We confirm these, but importantly our study involving
286 patients is the first to include all stages, histological subtypes
and all of CSS, OS and DFS, hence broadening the applicability.
Although the comparison of CRP with scoring systems, such as the
Kattan, UISS and SSIGN scores, has been made (Karakiewicz et al,
2007; Ramsey et al, 2008), we also show for the first time the
independence of CRP and several other biochemical and
haematological variables compared with a recently proposed pre-
operative prognostic algorithm. This may indicate a potential
contribution to such models, which may allow the more accurate
stratification of individuals for treatment and monitoring. Pre-
operatively, this could be of importance in determining patient
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Figure 1 Kaplan–Meier survival curves demonstrating the effect of CRP in relation to (A) CSS, (B) OS, (C) DFS and (D) non-cancer-related survival in
patients undergoing nephrectomy for RCC. The 5-year OS was 72% (95% CI 65–78%) for patients with a CRPp15mgl
 1 and 33% (95% CI 23–44%) for
patients with a CRP415mgl
 1 with corresponding 3-year OS being 84% (95% CI 78–89%) and 38% (95% CI 28–49%). The 5-year CSS was 83% (95% CI
76–88%) for patients with a CRPp15mgl
 1 and 37% (95% CI 26–49%) for patients with a CRP415mgl
 1 and corresponding 3-year CSS figures were
90% (95% CI 85–94%) and 42% (95% CI 32–54%). The 5-year DFS was 82% (95% CI 75–87%) for patients with a CRPp15mgl
 1 and 38% (95% CI
25–53%) for patients with a CRP415mgl
 1 with corresponding 3-year DFS being 86% (95% CI 80–90%) and 41% (95% CI 28–56%), respectively.
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Figure 2 Kaplan–Meier survival curves demonstrating the effect of
CRP in relation to CSS for clear cell histology (---) and non-clear cell
histology in patients undergoing nephrectomy for RCC.
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Univariate Multivariate
Variable v
2 HR HR CI
a P-value v
2 HR HR CI
a P-value c-Index
d
CSS
(a)
Log10(CRP) 66.1 4.4 3.1–6.3 o0.001 17.3 2.2 1.5–3.3 o0.0001 86.2
Age (continuous) 0.4 1.01 0.99–1.03 0.52 NS
Stage 87.7 3.0 2.3–3.9 o0.001 42.7 2.4 1.8–3.3 o0.0001 80.8
Grade 61.5 3.7 2.6–5.3 o0.001 8.9 1.8 1.2–2.7 0.003 86.7
T stage 60.9 3.1 2.2–4.3 o0.001 NS
N stage ( ve vs +ve) 34.0 6.1 3.8–10.0 o0.001 NS
M stage 66.2 7.3 4.7–11.6 o0.001 NS
Necrosis (Y/N) 43.5 4.8 3.0–7.7 o0.001 NS
MVI (Y/N) 63.9 7.2 4.2–12.4 o0.001 NS
Max tumour sizep50, 51–100, 4100 40.3 2.8 2.1–3.9 o0.001 NS
Gender 2.7
b 1.5 0.9–2.4 0.10 NS
Histology: clear cell vs rest 0.8
c 1.3 0.69–2.6 0.37 NS
RBC p4.25 vs 44.25 14.7 2.6 1.6–4.1 o0.001 6.7 2.0 1.2–3.2 0.009 87.6
Hb (continuous) 35.6 1.45 1.3–1.6 o0.001 NS
WBC p9.5 vs 49.5 6.8 2.0 1.2–3.4 0.009 7.1 2.2 1.3–3.7 0.008 86.3
Neuts p4.9 vs 44.9 16.1 2.7 1.6–4.5 o0.001 NS
Lymphs p1 vs 41 9.4 2.5 1.5–4.3 0.002 NS
Monos (continuous) 6.8 6.6 1.7–26 0.009 NS
Platelets p360 vs 4360 28.7 3.6 2.3–5.7 o0.001 NS
Log10(neuts/lymphs) 24.1 2.5 1.8–3.5 o0.001 8.3 4.2 1.6–11 0.004 87.5
Na p138 vs 4138 16.3 2.6 1.6–4.0 o0.001 NS
K p4.3 vs 44.3 10.3 2.2 1.3–3.5 0.001 NS
Urea (continuous) 0.1 1.01 0.94–1.1 0.80 NS
Log (creatinine) 0.01 1.03 0.55–1.9 0.92 NS
(b) OS
Log10(CRP) 50.9 3.1 2.3–4.1 o0.001 9.8 1.8 1.2–2.5 0.002 70.4
Age (continuous) 2.3 1.01 1.00–1.03 0.13 NS
Stage 48.2 1.8 1.5–2.2 o0.001 NS
Grade 34.5 2.2 1.6–2.8 o0.001 NS
T stage 33.7 1.9 1.5–2.4 o0.001 NS
N stage ( ve vs +ve) 36.2 4.7 3–7.2 o0.001 NS
M stage 44.0 4.2 2.8–6.3 o0.001 21.7 2.9 1.9–4.5 o0.0001 73.5
Necrosis (Y/N) 33.4 3.2 2.1–4.7 o0.001 7.8 1.9 1.2–2.9 0.005 76.3
MVI (Y/N) 44.0 3.8 2.5–5.6 o0.001 9.5 2.0 1.3–3.2 0.002 78.5
Max tumour size p50, 51–100, 4100 26.5 2.0 1.6–2.7 o0.001 NS
Gender 5.4
b 1.6 1.1–2.4 0.02 NS
Histology: clear cell vs rest 1.1
c 1.3 0.77–2.4 0.29 NS
RBC p4.25 vs 44.25 18.2 2.4 1.6–3.6 o0.001 9.6 2.0 1.3–3.0 0.002 77.2
Hb (continuous) 31.2 1.3 1.2–1.5 o0.001 NS
WBC p9.5 vs 49.5 12.8 2.2 1.5–3.4 o0.001 14.1 2.4 1.6–3.7 0.0002 75.4
Neuts. p4.9 vs 44.9 17.3 2.3 1.5–3.6 o0.001 NS
Lymphs. p1 vs 41 5.5 1.9 1.1–3.1 0.02 NS
Monos (continuous) 9.6 6.5 2.1–20.4 0.002 NS
Platelets p360 vs 4360 16.9 2.4 1.6–3.5 o0.001 NS
Log(neuts/lymphs) 20.1 2.1 1.5–2.8 o0.001 NS
Na p138 vs 4138 16.9 2.2 1.5–3.3 o0.001 NS
K p4.3 vs 44.3 8.1 1.8 1.2–2.6 0.004 NS
Urea (continuous) 2.8 1.04 1.0–1.09 0.09 NS
Log (creatinine) 2.9 1.5 0.98–2.2 0.09 NS
(c) DFS
CRP (p15 vs 415) 38.3 4.0 2.6–5.9 o0.001 23.2 2.9 1.9–4.4 o0.0001 83.9
Age (continuous) 1.4 1.01 0.99–1.04 0.23 6.1 1.03 1.01–1.06 0.01 85.5
Stage 60.1 3.3 2.3–4.7 o0.001 26.6 2.6 1.7–3.8 o0.0001 77.4
Grade 35.2 3.1 2.1–4.5 o0.001 NS
T stage 50.0 3.2 2.2–4.6 o0.001 NS
N stage ( ve vs +ve) 14.9 5.5 2.7–11.4 o0.001 NS
M stage –
Necrosis (Y/N) 30.1 4.7 2.7–8.0 o0.001 NS
MVI (Y/N) 39.0 5.6 3.2–9.9 o0.001 7.5 2.3 1.2–4.2 0.006 85.0
Max tumour sizep50, 51–100, 4100 35.0 3.1 2.1–4.6 o0.001 NS
Gender 4.9
b 1.9 1.05–3.3 0.03 NS
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streatment, such as selection of higher-risk patients, given the
advent of neo-adjuvant therapies, or in the case of advanced
disease those who most warrant cytoreductive nephrectomy with
its inherent risks. Conversely, in a post-operative setting, higher
risk patients may be identified for adjuvant therapies and/or
monitored more intensively, all of which have implications for
health economics and patient quality of life.
C-reactive protein is also associated with prognosis of other
tumour types and recently in a study involving 10408 individuals
observed over 16 years as part of the Copenhagen City Heart
Study; baseline levels of CRP were associated with increased risk of
developing cancer (Allin et al, 2009). Importantly, this study used a
high-sensitivity assay for CRP, allowing examination of values at a
higher level of resolution within the ‘normal’ interval. Further
analysis of CRP in two pooled prospective cohorts from the British
Women’s Heart and Health study and the Caerphilly cohort and a
meta-analysis also found an association with cancer risk (Heikkila
et al, 2009).
A criticism made in using CRP as a prognostic indicator is
its perceived low specificity owing to its being an acute-phase
reactant produced by the liver in a variety of inflammatory or
infectious diseases. However, highly significant discrimination
between RCC patients with poor and good outcome was possible,
and encouragingly CRP was not associated with non-cancer
death in our study. The use of repeated baseline measurements
(Ledue and Rifai, 2003; Pearson et al, 2003) may allow the impact
of subclinical or clinical acute inflammatory illnesses to be
determined. However, there is evidence in RCC that CRP is
produced by normal and malignant renal epithelial cells (Jabs et al,
2003, 2005) with a significant correlation between pre-operative
serum CRP and tissue CRP mRNA levels.
On multivariate analysis CRP clearly provides additional
information to the pre-operative model (Karakiewicz et al, 2009).
The small increase in predictive accuracy of about 2%, using
Harrell’s c-index, is not unexpected in such multivariate analyses.
Schemper and Henderson, (2000) state that ‘the likely amount of
predictive accuracy is often low even if there are highly significant
and relatively strong prognostic factors’. They recommend
graphical comparisons of survival curves and clearly the CRP
curves corresponding to the 2% improvement in predictive
accuracy are still widely separated even after allowing for the
nomogram score. This additional separation is interesting given
that one component of the nomogram is symptom scores, which
CRP may be expected to partly reflect. Our data shows that CRP is
Table 2 (Continued)
Univariate Multivariate
Variable v
2 HR HR CI
a P-value v
2 HR HR CI
a P-value c-Index
d
Histology:
Clear cell vs rest 0.52
c 1.3 0.6–2.8 0.47 NS
RBC p4.25 vs 44.25 3.1 1.7 0.97–3.1 0.08 NS
Hb (continuous) 8.7 1.25 1.1–1.4 0.003 NS
WBC p9.5 vs 49.5 0.66 1.3 0.7–2.6 0.42 NS
Neuts. p4.9 vs 44.9 4.1 1.75 1.0–3.0 0.04 NS
Lymphs. p1 vs 41 0.3 1.3 0.47–3.6 0.59 NS
Monos (continuous) 5.0 6.7 1.4–33.1 0.025 NS
Platelets p360 vs 4360 23.4 4.1 2.4–7.0 o0.001 NS
Log(neuts/lymphs) 3.3 1.5 0.98–2.4 0.07 NS
Na p138 vs 4138 2.8 1.6 0.93–2.8 0.10 NS
K p4.3 vs 44.3 2.4 1.5 0.89–2.6 0.12 NS
Urea (continuous) 1.13 1.05 0.97–1.1 0.29 NS
Log (creatinine) 0.32 1.25 0.6–2.6 0.57 NS
Abbreviations: CI¼confidence interval; CSS¼cancer-specific survival; DFS¼disease-free survival; HR¼hazard ratio; NS¼not significant; OS, overall survival. Units in table 2
are similar to those shown in table 1.
a95% confidence interval.
bWorse survival in male patients.
cClear cell with worse survival.
d% at inclusion of variable.
Estimated survival curves from Cox model for a
patient with mean nomogram score by CRP value
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Figure 3 (A) Survival (CSS) curves for our data by nomogram score (Karakiewicz et al, 2009). The 1-, 2- and 5-year estimates for our data (published
nomogram data) (Karakiewicz et al, 2009) are 91.9 (87.5%), 83.0 (80.2%) and 72.4% (73.9%), respectively. (B) Cox model predicted survival curves for a
patient having the mean nomogram score and CRP below and above 15, demonstrating the additional effect of CRP in predicting survival beyond the
nomogram score effect in patients undergoing nephrectomy for RCC.
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shighly correlated with many factors but in the multivariate linear
regression the overall r
2 value for log of CRP only reached 49% and
so 51% of the variability in CRP values is unexplained by factors
examined. This variable is, therefore, also measuring an indepen-
dent effect of some nature, and therefore has the potential to
predict effects of a previously unknown nature. Its objective
measurement and correlation with the other factors such as stage,
MVI, necrosis and TNM augurs well for its use as a monitoring
variable, as it is obviously related to other factors that are clearly
relevant, although not completely assessable before treatment.
In addition to CRP, several other routinely measured bio-
chemical and haematological parameters were shown to have
independent prognostic significance, including log of neutrophil/
lymphocyte ratio, serum sodium and WBC. Importantly these
provided additional information to the pre-operative score
(Karakiewicz et al, 2009) in this study. This is in contrast to a
previous smaller study (Ramsey et al, 2008) in which on
multivariate analysis apart from clinico-pathological variables
and the SSIGN, UISS and Kattan scores, only CRP but not other
haematological variables was significant for CSS or RFS. This
difference is most likely because of the more heterogeneous cohort
in our study, as when the patients with metastatic disease were
excluded, the neutrophil/lymphocyte ratio was then no longer
independently significant. Our model therefore has identified other
parameters that could be of value in an integrated scoring system.
This is the first report of the neutrophil/lymphocyte ratio as an
independent predictive factor of survival in RCC patients, although
previously described in other cancers such as ovarian cancer (Cho
et al, 2009).
The concept of using additional measurable biomarkers together
with clinico-pathological scoring systems is so far restricted to
tissue with promising markers, including p53, vimentin and CAIX
(Kim et al, 2004) or Ki-67, p53, endothelial/epithelial VEGFR1 and
epithelial VEGF-D (Klatte et al, 2009). C-reactive protein is even
more attractive being a routinely, relatively inexpensive and
objectively measured analyte available pre-operatively. The addi-
tional value of this and other routinely measured biochemical and
haematological variables with pre-operative nomograms such as
that proposed by Karakiewicz et al (2009) should now be explored
further prospectively in a larger series of patients. Such studies
should include consideration of any known potential confounding
factors such as BMI, smoking or HRT (Ledue and Rifai, 2003;
Heikkila et al, 2007) and the role of co-morbidities and
environmental factors in influencing an individual’s baseline value
as exemplified in cardiovascular disease (Ruckerl et al, 2009) in
which high-sensitivity CRP measurements are currently used in
risk assessment (Pearson et al, 2003).
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